D-0133-2017 Class II Terminated

Recalled by Sandoz Inc — Princeton, NJ

FDA drug recall D-0133-2017 was initiated by Sandoz Inc on Aug 24, 2016 and is designated Class II. Reason for recall: Defective Delivery System; reports of damaged product that may alter the predicted release of scopolamine following transdermal application. The recall status is terminated (terminated Jun 7, 2017). Affected quantity: 42,740 cartons (24 count carton from 7 total lots).

Recall details

Product Type
Drugs
Report Date
Nov 16, 2016
Initiation Date
Aug 24, 2016
Termination Date
Jun 7, 2017
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
42,740 cartons (24 count carton from 7 total lots)

Product description

Transderm Scop (scopolamine) Transdermal System, 1.5 mg, 24 patches Multi pack, Rx only, Marketed by Baxter Healthcare Cop/Novartis, Deerfield, IL 60015, Manufactured by:Alza Corporation, Vacaville, CA 95688 for Novartis Consumer Health Inc., Parsippany, NJ 07054

Reason for recall

Defective Delivery System; reports of damaged product that may alter the predicted release of scopolamine following transdermal application.

Distribution pattern

TN

Code information

NDC 10019-553-02 (24 ct. carton) and NDC 10019-553-88 (patch); Lot #'s FV5908 and FX1520 both with expiry 06/2018; GB4910 and GC4210 both with expiry 09/2018; GE1927 with expiry 12/2018; GF7017 with expiry 01/2019 and GH8065 with expiry 02/2019.

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0133-2017
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0133-2017. Report a data issue: hello@regdatalab.com.